arrow
V

Valeria Santini

university of florence
H指数:63
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS)

基于低甲基化制剂治疗的反应对高风险骨髓增生异常综合征/肿瘤患者生存结局的影响:考虑基线临床-分子风险和移植状态的国际骨髓增生异常综合征联盟(icMDS)分析

2026-08-280
PRE
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax—an analysis from the International Consortium for MDS (icMDS) VALIDATE database

高风险骨髓增生异常综合征/新生物患者接受去甲基化药物+维奈克拉治疗后的结局分析——国际骨髓增生异常综合征(icMDS)VALIDATE数据库分析

2026-06-290
OAAI
Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes

治疗相关细胞减少症与低危骨髓增生异常综合征患者对imetelstat临床反应之间的关联

2026-04-070
OAAI
Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat

接受伊美替拉stat治疗低风险骨髓增生异常新生物患者的克隆性负荷调节

Leukemia
IF13.4
2026-01-120
OAAI
Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS

前期疗法对依赖输血、ESA复发或难治/不适用LR-MDS患者中imetelstat临床活性的影响

2025-12-310
OAAI
Clinical outcomes and safety in patients with lower-risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial

低危骨髓增生异常综合征患者接受伊米替列stat治疗后的临床疗效与安全性:IMerge三期试验的子研究

2025-11-010
OAAI
Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms

国际骨髓增生异常综合征/骨髓肿瘤工作组关于骨髓报告标准化的共识

2025-10-010
OA
IMPACT OF PRIOR TREATMENTS ON THE CLINICAL ACTIVITY OF IMETELSTAT IN PATIENTS WITH TRANFUSION-DEPENDENT (TD), ERYTHROPOIESIS-STIMULATING AGENT (ESA) RELAPSED/REFRACTORY/INELIGIBLE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS)

既往治疗对输血依赖性(TD)、促红细胞生成剂(ESA)复发/难治/不适用低危骨髓增生异常综合征(LR-MDS)患者中imetelstat临床活性的影响

2025-09-010
OAAI
ACQUISITION OF MOLECULAR ALTERATIONS IN UNTREATED-LOW RISK MYELODYSPLASTIC SYNDROMES IS ASSOCIATED WITH POOR PROGNOSIS

未治疗低风险骨髓增生异常综合征中分子改变的发生与不良预后相关

2025-09-010
PRE
IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score

IPSS-M风险和特定性别相关的体细胞突变预测LR-MDS对ESA疗法的反应:构建一个新评分

Blood
IF23.1
2025-06-270
PRE
Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS

他米巴罗替与阿扎胞苷联合治疗新诊断高危骨髓增生异常综合征(MDS)的SELECT-MDS-1三期研究的关键结果

2025-05-090
OAAI
Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/SyndromesdRecommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])

骨髓增生异常肿瘤/综合征的诊断和分类的当代方法国际骨髓增生异常肿瘤/综合征联合会 (MDS [icMDS]) 的建议

2024-12-011
PRE
Luspatercept versus epoetin alfa in erythropoiesisstimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial
2024-09-011
PRE